Ionis Pharmaceuticals (NASDAQ: IONS) has experienced a notable increase in its stock price target, rising from $73.00 to $77.00 according to a report released by analysts...
Ionis Pharmaceuticals, Inc. announced that it will present detailed findings from its pivotal Phase 3 CORE and CORE2 studies of olezarsen during a late-breaking session at...